Glaukos Shares Face Pressure Despite Record Quarterly Performance

Glaukos Corporation reported exceptional financial results for its second quarter, yet its stock experienced notable selling pressure in subsequent trading. The market’s reaction stands in contrast to the company’s strong operational metrics and upgraded annual guidance.

For Q2 2025, Glaukos announced consolidated net revenues of $124.1 million, representing a significant 30 percent year-over-year increase. The company’s core U.S. glaucoma business demonstrated even more robust growth, surging 45 percent to reach $72.3 million. The standout performer was clearly iDose TR, the intracameral delivery system that generated approximately $31 million in revenue, demonstrating impressive market adoption.

Although the company reported a net loss of $19.7 million, this figure represents substantial improvement from the $50.5 million loss recorded during the same period last year. Glaukos maintains strong Read more...